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S_y In UK Hodgkin's disea is usualy treated by eithr chnical oncologists or haematologists. A
national sudy of the of bone marrow xamiation m newly Hodgkin's disea was
to curmt pracice. A total of 620 questonnaires were and repls were
received from 60% of nsuhants (45% of linical oncologists and 70% of tokogists). Bone marrow
examination was perfoed in all new ca signifantly more often by tologs than by ciniCal
onc_ogits (74% vs 40'/!, P<0.001). Among haematologists, there was no correlation betwee the number of
new patients sn annually and practic, however cinical oncologists wer even lss likely to perform routine
bone marrow bopsis ifthey saw more than ten patients per year (P<0.02). Where bone marrow examination
perfor ed ively, the most common criteria used were peripheral bood cytoipa and
disase. These aiteria we appled in the same way by both cliical oncoloists and toois Bone
marrow biopsy, an invasive and often painfl procedur, is currently performed more frequently in Hodgkin's
disea than can be rommended on the basis of reoot studies in the literature and
Thr is a significant diffeee m practce between chnw oncologists and aematologists, and this raise the
wider issue of the inflce of hospital specialisation on patiet manamgent
KIey Hodgkin's diseas; bone marrow
Hodgkin's disease is a well-characterised lymphoma with a
widely accepted histological cassification and staging system
(Urba et al., 1992). In the UK patients with the disease are
normally referred for assessment and treatment to either
clinical oncologists or hmatologists. Over the last 20 years
many aspects of managet have changed. The introduc-
tion of new g technolgy has led to a revision of
pnorities for routine investigation with a reduced require-
ment for invasive procedures such as laparotomy. It has been
the authors' impreon that there is currently little consensus
as to the importance of bone marrow examination in newly
diagnosed patients.
Tlhis study of the practice of examining the bone marrow
in newly diagnosed Hodgkin's disea was undertaken to
establsh current practice in the UK. We aimed to determine
the degree of variability in the frequency with which this
investigation is performed, the extent of conformity with
published guidelnes and whether there was significant
difference in practice between clinical oncologists and
hematologists.
Meto
Consultant clinical oncologists and haematologists currently
sing in the UK were identified from records of the
Royal Colkege of Pathology and the Faculty of Clnical
Oncology of the Royal Colkge of Radiologists. Each consul-
tant was sent the questionnaire illustrated in the appendix.
Those not replying were prompted with a further question-
naire 4 weeks later.
Statistical methods
Comparisons between groups were made using the chi-square
test or FLsher's exact test.
ResBks
A total of620 questionnaires were despatched, 260 to clinical
oncologists and 360 to haematologists. Following prompting,
370 (60%) replies were received, 117 (45%) from clinical
oncokogsts and 253 (70%) from haematologists. Of those
responding to the questionnaire, 17 (15%) clincal oncologists
and 67 (26%) haematologists did not see patients with Hodg-
kin's disease and were excluded from further analysis.
Tbirty-one (11%) consultants saw more than ten cases per
year, 129 (45%) 5-10 cases and 125 (44%) fewer than five
cases. Haematologists were more likely than clinical
oncologists to see fewer than five new referrals per annum
(P<0.001).
Routine bone marrow examination in all patients was
performed significantly more often by haematologists than by
linial oncologists (74% vs 40%, P<0.001). Among
hematologists the decision to perform bone marrow
examination in patients selctively was not affected by the
number of patients with Hodgin's disease seen. However,
clinical oncologists were less likely to perform a routine bone
marrow if they saw more than ten patients per year than if
they saw fewer than ten patients (0.02>P>0.01).
Where bone marrow examination was performed selec-
tively the criteria used are ilulstrated in Table I. The most
common criteria used to iecide upon bone marrow examina-
tion were ripheal ood cytopenia (particularly throm-
bocytopenia), advanced stage disease and logistical con-
siderations such as the likelihood offuture transplantation or
entry into a study protocol. These criteria were applied in the
same way by both clinical oncologists and haematologists.
The number of cinicans performing bone marrow
examination in all patients did not differ in different regions.
Most cliicians performed bone marrow trephines at one site,
only 9% at two sites and less than 1% at three sites with no
difference between specialties. Bone marrow trephines were
mviewed by haematologists alone in 40% of cases. A com-
bined review with a histopathologist was performed in 50%
and histopathologists alone performed review in 10%. No
cinicians had change their reasons for bone marrow
examination over the previous 2 years.
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Table I Criteria used where bone marrow examination performed
selectively
Criteria for Cluincal
bone marrow examination oncologists Haematologists All
Thrombocytopenia 53 (93%) 46 (94%) 99 (94%)
Leucopenia 51 (89%) 43 (88%) 94 (89%)
Hb outside normal range 41 (72%) 37 (76%) 78 (74%)
Other peripheral blood 31 (54%) 27 (55%) 58 (55%)
abnormality
High erythrocyte 15 (26%) 7 (14%) 22 (21%)
sedimentation
rate/plasma viscosity
Advanced-stage diseas 37 (65%) 26 (53%) 63 (59%)
B symptoms 32 (56%) 17 (35%) 49 (46%)
Requirement of study 44 (77%) 32 (65%) 76 (72%)
protocol
Request by other consultant 7 (12%) 18 (37%) 25 (24%)
Patient eligible for future 31 (54%) 29 (59%) 60 (57%)
auto/allograft
Other 4 (7%) 5 (10%) 9 (8%)
It is well recognised that marrow infiltration by malignant
cells occurs in approximately 10% of cases of newly present-
ing Hodgkin's disease (Bartd et al., 1982; Schmid et al., 1992;
Stark et al., 1992; Urba et al., 1992). This is closely
associated with advanced clinical stage, and is found in only
1-2% of patients otherwise staged as I or H (Bartl et al.,
1982). In biopsies not infiltrated by malignancy other abnor-
malities, most commonly a mixed inflammatory cell infiltrate
may be seen, but these non-specific changes appear to have
limited prognostic signi n and do not influence the stag-
ing or treatment ofthe disease (Bartl et al., 1982). A study of
613 cases of Hodgkin's disease in the UK (Macintyre et al.,
1987) found that the bone marrow biopsy result affected the
mode of treatment in less than 1% of patients. A French
study indicated it was only contributory in patients with 'B'
symptoms (Eghbali et al., 1993). In view of the rarity of
marrow infiltration in early-stage disease and the limited
impact on patient manageme-t, recent guidelines have
generally recommended reserving bone marrow biopsy for
selected patients. Thus the Cotswold Meeting Committee
suggested bone marrow examination be restricted to patients
with stage IHI-IV or adverse stage II disease (Lister et al.,
1989) and the British National Lymphoma Investigation pro-
tocols designate the procedure as 'non-mandatory' unlss
autotransplantation is planned (Macintyre et al., 1987).
Our study demonstrates that, despite these guidelines, the
majority of patients with newly presenting Hodgkin's disease
in the UK have a bone marrow biopsy performed irestive
of stage or other criteria. Haematologists are signifiantly
more likely than clinical oncologists to biopsy marrow
routinely. Whereas haematologists' practice appears not to be
influenced by the number of cases of Hodgkin's disease they
see annually, clinical oncologists with greater experience of
treating Hodgkin's disease were less likely to biopsy
routinely. Such widespread marrow examination in all cases
suggests that many patients are having an invasive investi-
gation with only a minimal chance of the result influencing
their management.
Whae bone marrow examination was performed selec-
tively, both groups of clinicians had the same priorities.
There was a uniform lack of concordance with the Cotswold
guideines (Lister et al., 1989), more emphasis being placed
on peripheral blood abnormalities than the clnical stage of
disease. The majority of clinicans only sampled at one site,
despite evidence that where bone marrow examination is
indicated bilateral biopsies signintly increase the pro-
bability of detecting infiltration (Bartl et al., 1982).
The difference in practice between clinical oncologists and
haematologists is of particular interest. With the increasing
fragmntation of hospital medicine clinicians within different
specialities have different clinical experience and post-
graduate training. Ease of access to investigational and treat-
ment facilities is also vanable. Patients with identical clinical
characteristics may be referred to different specialties. The
demonstrable difference in approach to bone marrow
examination in Hodgkdn's disease between clinical
oncologists and haematologists is likely to have parallels in
other diseases and other specialties. Such variability in the
management of a discrete clinical problem by different
specialties is undesirable, as rational medical management
should presumably be based on clinical characteristics rather
than practitioner-associated factors.
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1. Do you have responsibilty for the care/mangement of patients with Hodgkin's disease?
a Yes a No
If ., there is no nel to answer any further questions. Pkase could you return this form to complete our records.
If y, please complete the remaining questions.
2. How many new patients with Hodgkin's disea do you see in a year?
EJ <5 0 5-10 El 10+
3. Do you cxamine the bone marrow in all your patients with Hodgkin's disea at presentation?
J Yes E No
4. If no, which of the following would make you consider performing a bone marrow at diagnosis?
EJ Hb outside normal range
0Leucopenia
O Thrombocytopenia
E Other pripheral blood abnormality
EHigh ESR/plasma viscosity
EAdvanced stage disease (specify):
OB symptoms
E Requrment of study protol
E Request by other consultant
El Patient eligible for future auto/allograft
ElOther (seify):
5. Wben you perform a bone marrow do you routinly biopsy?
a One site El Two sites El Four sites
6. Who rniews your trephine biopsies?
El Haematologist El Histologist
E Both of above E Other (specify):
7. Have you changed your policy for doing bone marrow examinations in the last two years (since 01.01.91). If so, please could you tell us why?